Explore

Trendline Trendline
Sequenex Partners with MedTech Innovator to Boost Medical Technology Startups

Sequenex Partners with MedTech Innovator to Boost Medical Technology Startups

Sequenex Partners with MedTech Innovator to Boost Medical Technology Startups
Trendline Trendline
Insulet Corporation Launches Pivotal Study for Automated Insulin Delivery System for Type 2 Diabetes

Insulet Corporation Launches Pivotal Study for Automated Insulin Delivery System for Type 2 Diabetes

Insulet Corporation Launches Pivotal Study for Automated Insulin Delivery System for Type 2 Diabetes
Rapid Read Rapid Read
Lumicell Expands Scientific Engagement at ASBrS 2026, Enhancing Breast Cancer Surgery Techniques

Lumicell Expands Scientific Engagement at ASBrS 2026, Enhancing Breast Cancer Surgery Techniques

Lumicell, a leader in intraoperative fluorescence imaging technology, has announced its expanded presence at the American Society of Breast Surgeons (ASBrS) 2026 Annual Meeting in Seattle. The company is showcasing its LumiSystem, designed to illuminate residual cancer in the breast cavity post-lumpectomy. Lumicell's participation includes hands-on technology demonstrations, scientific data presentations, and educational sponsorships. The company aims to engage with the breast surgery community to advance intraoperative visualization and support surgeons in making critical decisions during breast-conserving surgery. Lumicell's technology will be featured in a scientific poster session, highlighting the performance of Pegulicianine Fluorescence Guided Evaluation of Lumpectomy Cavities. Additionally, Lumicell is sponsoring educational courses for the next generation of breast surgeons, emphasizing its commitment to surgical education.
Rapid Read Rapid Read
NHS Introduces Injectable Cancer Treatment to Reduce Hospital Time

NHS Introduces Injectable Cancer Treatment to Reduce Hospital Time

The NHS has introduced a new injectable form of the cancer drug Keytruda, which could significantly reduce the time patients spend in hospitals. Previously administered through intravenous infusion, the new method allows the drug to be given as a quick injection, potentially saving hours for both patients and healthcare staff. Keytruda, a type of immunotherapy, helps the body's immune system attack cancer cells and is used to treat multiple types of cancer. This development follows the introduction of similar injectable treatments, such as Opdivo, in some hospitals last year.
Rapid Read Rapid Read
North Metro Fire Department Implements New Technology to Enhance Patient Monitoring

North Metro Fire Department Implements New Technology to Enhance Patient Monitoring

The North Metro Fire Department has introduced new technology aimed at improving the monitoring of patients during emergency calls. This initiative is part of the department's efforts to enhance the quality of care provided to individuals in critical situations. The technology is designed to offer real-time data on patients' vital signs, which can be crucial in making timely and informed medical decisions. This development marks a significant step forward in emergency medical services, potentially increasing the chances of survival and recovery for patients by providing first responders with more accurate and immediate information.
Rapid Read Rapid Read
FDA Approves Incyte's Jakafi XR for Myelofibrosis, Polycythemia Vera, and Graft-Versus-Host Disease

FDA Approves Incyte's Jakafi XR for Myelofibrosis, Polycythemia Vera, and Graft-Versus-Host Disease

The U.S. Food and Drug Administration (FDA) has approved Jakafi XR, an extended-release formulation of ruxolitinib, for the treatment of several conditions including intermediate- or high-risk myelofibrosis (MF), polycythemia vera (PV) in adults intolerant to hydroxyurea, and both acute and chronic graft-versus-host disease (GVHD) in patients aged 12 and older. Jakafi XR is a once-daily tablet that provides consistent drug exposure comparable to the twice-daily immediate-release version. This approval is based on clinical studies demonstrating bioequivalence between the two formulations. The drug is expected to be available for pharmacy orders by May 8. Incyte, the company behind Jakafi XR, emphasizes its commitment to providing treatment options that meet the evolving needs of patients with myeloproliferative neoplasms and GVHD.
Rapid Read Rapid Read
Lumicell Expands Scientific Engagement at ASBrS 2026 Annual Meeting to Enhance Breast Cancer Surgery

Lumicell Expands Scientific Engagement at ASBrS 2026 Annual Meeting to Enhance Breast Cancer Surgery

Lumicell, a company specializing in intraoperative fluorescence imaging technology for breast cancer surgery, has announced its expanded presence at the American Society of Breast Surgeons (ASBrS) 2026 Annual Meeting. The event is being held from April 29 to May 3, 2026, at the Seattle Convention Center. Lumicell is showcasing its LumiSystem, which aids in detecting residual cancer in the breast cavity post-lumpectomy. The company is conducting live demonstrations, scientific data presentations, and educational sponsorships to engage with the breast surgery community. Lumicell's technology will be featured in the ASBrS scientific poster session, highlighting its role in fluorescence-guided surgery. The company is also sponsoring educational programs for breast surgery fellows, emphasizing its commitment to advancing surgical education.
Rapid Read Rapid Read
Sonire Therapeutics Begins U.S. Clinical Trial for Pancreatic Cancer Treatment

Sonire Therapeutics Begins U.S. Clinical Trial for Pancreatic Cancer Treatment

Sonire Therapeutics has initiated its first U.S. clinical trial, SUNRISE-II, to evaluate its High-Intensity Focused Ultrasound (HIFU) therapy system for treating pancreatic cancer. The trial aims to assess the safety and feasibility of this minimally invasive, anesthesia-free treatment. The HIFU system uses real-time ultrasound guidance to target and ablate tumors, potentially offering a less invasive alternative to traditional cancer treatments. This trial marks a significant step in Sonire's U.S. clinical development and regulatory strategy.
Trendline Trendline
Xenco Medical Honored as TIME100 Most Influential Company in Health

Xenco Medical Honored as TIME100 Most Influential Company in Health

Xenco Medical Honored as TIME100 Most Influential Company in Health
Rapid Read Rapid Read
Beth Israel Lahey Health Expands AI Scribe Technology to Combat Physician Burnout

Beth Israel Lahey Health Expands AI Scribe Technology to Combat Physician Burnout

Beth Israel Lahey Health (BILH), based in Boston, is expanding the use of Heidi's AI scribe technology across its entire health system. This decision follows a successful six-month pilot program involving 1,000 providers. The AI scribe, developed by Australia-based Heidi, is designed to alleviate administrative burdens by automating transcription services and integrating with electronic health records. The expansion will now provide 6,000 providers across BILH's 14 hospitals and 175 primary care practices access to this technology. The AI scribe allows healthcare providers to review patient history and notes before appointments and automatically updates electronic health records post-consultation. The initial deployment showed high satisfaction rates among users, with 89% satisfied with note quality and 90% feeling more present with patients.
Trendline Trendline
Xenco Medical Honored as TIME100 Most Influential Company for Healthcare Innovations

Xenco Medical Honored as TIME100 Most Influential Company for Healthcare Innovations

Xenco Medical Honored as TIME100 Most Influential Company for Healthcare Innovations
Trendline Trendline
ResMed's Q1 Results Surpass Expectations Amid Mask Portfolio Growth and CFO Transition

ResMed's Q1 Results Surpass Expectations Amid Mask Portfolio Growth and CFO Transition

ResMed's Q1 Results Surpass Expectations Amid Mask Portfolio Growth and CFO Transition